


COVID-19

MVC-COV1901

VACCINE PROFILE

Attributes	Description
Technology	CHO cell derived spike protein (Subunit)
Route of administration	Intramuscular
Dosage schedule	2 doses 4 weeks apart
Target population	Adults >20 years of age, including the elderly. Ongoing age-de-escalation study to adolescents
Formulation	Liquid, S-2P protein (15 mcg) + CpG 1018 (750 mcg) + Al(OH) ₃ (375 mcg)
Volume	0.5 mL
Packaging	Pre-filled Syringe, Multiple Dose Vial (10 doses/vial)
Storage	Cold Chain, 2-8C




MEDIGEN VACCINE BIOLOGICS CORP

Image Source: Wikipedia, the free encyclopedia



PHASE II IMMUNOGENICITY SARS-CoV-2 NEUTRALIZING ANTIBODY TITERS



All: 408IU, 20 to <65 Years: 454IU, >=65years: 296 IU, HCS=229 IU

Preliminary Interim Data

Anti-Spike IgG from Phase I and Phase II Sera Measured by WHO anti-SARS-CoV-2 International Standard (BAU/mL)


Phase I

LD	V2	V4	V5	V7	V8	V9
GMT	55	105	354	7178	3763	1481
BAU/mL	5	10	32	655	343	135
MD	V2	V4	V5	V7	V8	V9
GMT	50	134	622	7746	4719	1759
BAU/mL	5	12	57	706	430	160
HD	V2	V4	V5	V7	V8	V9
GMT	55	241	526	11221	9299	2537
BAU/mL	5	22	48	1023	848	231

Phase II

		D29	D43	D57
All	GMT	430.48	8262.17	5745.35
	BAU/mL	39	754	524
≥ 20 to < 65	GMT	524.24	9637.58	6520.85
	BAU/mL	48	879	595
≥ 65	GMT	233.05	5125.71	3887.09
	BAU/mL	21	467	355

Neutralizing Antibody Titres after 3rd boost Measured by WHO anti-SARS-CoV-2 International Standard (IU/mL)



Fold-Reduction of Neutralizing Antibody Titres Against Delta Strain Compared to Wildtype, using Sera after 3rd Boost

